【朗報】新型コロナ飲み薬「モルヌピラビル」をイギリスが世界初承認　ネット「変異しても効くの？」「アナウンサー泣かせ」「アビガンは？」

メルクのニュースリリースページより

Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World - Merck.com

U.K.’s Medicines and Healthcare Products Regulatory Agency Authorizes Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults With a Positive SARS

www.merck.com

↑より引用
KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. In the U.K., LAGEVRIO® (lah-GEV-ree-oh) is the planned trademark for molnupiravir; the trademark for molnupiravir in other countries has not been approved. Merck announced its application with the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of molnupiravir is under review and recently announced the European Medicines Agency has initiated a rolling review of the company’s Marketing Authorization Application. Merck is actively working to submit applications to other regulatory agencies around the world.

大体が記事の内容と同じですね。
対新型コロナに心強い武器が一つ加わりました。米国食品医薬品局（FDA）も審査中。日本も続いてほしいですね。

【朗報】米製薬大手メルク「入院・死亡リスクが半減」　新型コロナ“飲み薬”の中間分析　ネット「762例治験で死亡者ゼロ⁉」「アビガンと同じRNA阻害系？」

blog.yorolog.com